CLEAR III Intraventricular Thrombolysis Trial
Resolving IVH to improve outcomes
Home
Site Start-up
Study Documents
About Us
Contact Us
Participating Sites
Links

Welcome to the CLEAR III Home Page

 
CLEAR III is a Phase III randomized clinical trial (RCT) using recombinant tissue plasminogen activator (rtPA, Cathflo® Activase,® Genentech, Inc., San Francisco, CA) to treat subjects with intracerebral hemorrhage (ICH), intraventricular hemorrhage (IVH), and hydrocephalus.


The primary aim of the study is to determine whether rapid removal of IVH clot with low-dose rtPA more likely improves modified Rankin Scores at 6 months (Rankin 0-3) compared to subjects treated with best medical care alone.

Start Up Meeting Materials Posted 

     

Click here to view the slide shows and presentation materials shown at the recent CLEAR III Investigator and Coordinator meetings. 

  Pharmacist Training Sessions  


Updated dates and times for the CLEAR III Pharmacist Training sessions have been posted.  Click here to register for an upcoming session.  

 

The CLEAR III Trial is led by Study Chairman and co-Principal Investigator Dr. Daniel Hanley of

Johns Hopkins Medicine.  The study Surgical Center at NorthShore University HealthSystem (an affiliate of the University of Chicago Hospitals) is led by co-Principal Investigator Dr. Issam Awad.